Astromech, an AI company that uses genomic data to predict biological change, secured $20 million in funding at a $3.8 billion valuation. The round brings the company's total funding to $60 million.
Astromech develops predictive AI models trained on genomic data to forecast biological outcomes and changes. The funding positions the startup within the growing intersection of artificial intelligence and precision medicine.
The $20 million investment values the company at $3.8 billion, reflecting investor confidence in genomic AI applications. With $60 million in total capital raised, Astromech has secured substantial backing to scale its platform.
Genomic AI models have attracted significant venture interest as researchers and companies explore how machine learning can unlock insights from DNA sequences. Applications span drug discovery, disease prediction, and personalized medicine.
Astromech joins a cohort of AI-powered biotech startups targeting computational biology challenges. The company's valuation suggests strong market appetite for tools that translate genetic information into actionable predictive models.
Andreessen Horowitz's Borderless Founder network backs immigrant and international entrepreneurs, arguing that straddling home countries and Silicon Valley creates competitive advantages in AI development.
Y Combinator-backed Apollo Atomics is miniaturizing a previously overlooked nuclear reactor component to reduce electricity costs below natural gas prices.
Anthropic-backed enterprise AI venture Ode has acquired four-year-old AI consultancy Casper for an undisclosed amount. The move marks Ode's second acquisition since launching in July.
London-based Callosum has raised $100M in seed funding to scale its software platform that automatically matches AI workloads to optimal models and hardware. The round was led by Atomico and the UK Sovereign AI Fund.